StockData
Monopar Therapeutics logo

Monopar Therapeutics (MNPR) stock

MNPRNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 7/30
$71.06−0.91 (-1.26%)

Close on Nov 17, 2026Market cap $476.97MP/E –Yield –

Monopar Therapeutics operating cash flow

Operating cash flow is the cash the business generates from its day-to-day operations.

Monopar Therapeutics's operating cash flow for the twelve months ending Jun 30, 2026 was -$12.18M. For fiscal 2025 it was -$12.20M. The highest annual figure on record is -$1.19M in fiscal 2016.

Annual operating cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$12.20M–
FY2024Dec 31, 2024-$6.40M–
FY2023Dec 31, 2023-$7.86M–
FY2022Dec 31, 2022-$7.23M–
FY2021Dec 31, 2021-$7.32M–
FY2020Dec 31, 2020-$4.66M–
FY2019Dec 31, 2019-$3.02M–
FY2018Dec 31, 2018-$2.68M–
FY2017Dec 31, 2017-$2.63M–
FY2016Dec 31, 2016-$1.19M–

Quarterly operating cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$3.25M–
Q1 FY2026Mar 31, 2026-$3.47M–
Q4 FY2025Dec 31, 2025-$3.37M–
Q3 FY2025Sep 30, 2025-$2.09M–
Q2 FY2025Jun 30, 2025-$1.08M–
Q1 FY2025Mar 31, 2025-$5.66M–
Q4 FY2024Dec 31, 2024-$2.00M–
Q3 FY2024Sep 30, 2024-$1.07M–
Q2 FY2024Jun 30, 2024-$1.68M–
Q1 FY2024Mar 31, 2024-$1.66M–
Q4 FY2023Dec 31, 2023-$1.55M–
Q3 FY2023Sep 30, 2023-$1.94M–
Q2 FY2023Jun 30, 2023-$2.10M–
Q1 FY2023Mar 31, 2023-$2.27M–
Q4 FY2022Dec 31, 2022-$1.30M–
Q3 FY2022Sep 30, 2022-$2.15M–
Q2 FY2022Jun 30, 2022-$1.31M–
Q1 FY2022Mar 31, 2022-$2.47M–
Q4 FY2021Dec 31, 2021-$2.03M–
Q3 FY2021Sep 30, 2021-$1.94M–
Q2 FY2021Jun 30, 2021-$1.41M–
Q1 FY2021Mar 31, 2021-$1.94M–
Q4 FY2020Dec 31, 2020-$1.24M–
Q3 FY2020Sep 30, 2020-$1.30M–
Q2 FY2020Jun 30, 2020-$995.47K–
Q1 FY2020Mar 31, 2020-$1.13M–
Q4 FY2019Dec 31, 2019-$668.71K–
Q3 FY2019Sep 30, 2019-$613.27K–
Q2 FY2019Jun 30, 2019-$739.74K–
Q1 FY2019Mar 31, 2019-$995.97K–
Q4 FY2018Dec 31, 2018-$519.21K–
Q3 FY2018Sep 30, 2018-$599.56K–
Q2 FY2018Jun 30, 2018-$752.86K–
Q1 FY2018Mar 31, 2018-$808.85K–
Q4 FY2017Dec 31, 2017-$816.02K–
Q3 FY2017Sep 30, 2017-$1.19M–
Q2 FY2017Jun 30, 2017-$305.13K–
Q1 FY2017Mar 31, 2017-$311.49K–

More Monopar Therapeutics figures

See a number that looks wrong?